Veterinary Intravenous (IV) Solutions Market Report 2025

This veterinary intravenous (IV) solutions market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The veterinary intravenous (IV) solutions market size has grown strongly in recent years. It will grow from $1.5 billion in 2024 to $1.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing number of veterinary clinics, rise in incidence of dehydration, growth in livestock farming, rise in the number of companion animals, and growth in veterinary diagnostics.

The veterinary intravenous (IV) solutions market size is expected to see strong growth in the next few years. It will grow to $2.19 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising adoption of pet insurance, increasing animal healthcare expenditure, growing awareness of animal healthcare, rising incidence of animal diseases, and increasing pet insurance coverage. Major trends in the forecast period include technological advancements, diverse product formulations, telemedicine integration, advanced veterinary intravenous (IV) delivery systems, and smart veterinary intravenous (IV) systems.

The growing prevalence of various animal diseases is anticipated to drive the expansion of the veterinary intravenous (IV) solutions market. Animal diseases are conditions that negatively affect the health and function of animals, with common examples including anthrax, leptospirosis, rabies, canine distemper, and heartworm disease. The rise in these diseases is attributed to factors such as intensive farming practices, wildlife encroachment, and antibiotic resistance. Veterinary IV solutions play a crucial role in rehydrating animals suffering from dehydration caused by illnesses such as gastroenteritis or severe infections, thereby ensuring proper hydration and supporting overall health. For instance, the American Veterinary Medical Association reported in July 2024 that there were 345 confirmed cases of rabies in domestic animals in 2022, a 10.9% increase from the 311 cases in 2021. Thus, the increase in animal diseases is boosting the growth of the veterinary IV solutions market.

Rising expenditure on animal health products is also expected to propel the growth of the veterinary intravenous (IV) solutions market. Animal health products include medications, supplements, and treatments aimed at maintaining or improving animal health. The rise in spending on these products is driven by factors such as increased pet ownership, greater awareness of animal health, advancements in veterinary care, and the need for improved disease prevention and treatment. Veterinary IV solutions contribute to this trend by addressing urgent medical needs and enhancing veterinary care. For example, the Republic of Estonia Agency of Medicines reported in March 2024 that the veterinary medicinal products market grew by 6.9% in 2023, reaching $20.54 million (18.6 million euros), up from $19.21 million (17.4 million euros) in 2022. This increase in spending on animal health products is driving the growth of the veterinary IV solutions market.

Leading companies in the veterinary IV solutions market are focusing on developing advanced products, such as fluoroquinolone antibiotics, to enhance efficacy and safety. Fluoroquinolones are a potent class of antibiotics used in both human and veterinary medicine to treat a variety of bacterial infections, with careful management to prevent resistance and side effects. For example, in April 2024, Elanco, a US-based pharmaceutical company, introduced Pradalex, a pradofloxacin injection solution approved by the US Food and Drug Administration (FDA). This 3rd generation fluoroquinolone is approved for treating swine respiratory disease (SRD) caused by several pathogens, including Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, streptococcus suis, and mycoplasma hyopneumoniae. The drug's label advises that it should be used only after other non-fluoroquinolone treatment options have been considered.

Major companies operating in the veterinary intravenous (IV) solutions market are Merck & Co. Inc., Baxter International Inc., Zoetis Inc., Fresenius Kabi AG, Elanco Animal Health Incorporated, B. Braun Melsungen AG, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol SA, Norbrook Laboratories Limited, Ceva Santé Animale, Revival Animal Health Inc., Aromor Animal Health, Jorgensen Laboratories LLC, Pharmacosmos AS, Sykes Veterinary International Pty Ltd., Rusoma Laboratories Private Limited, Patterson Companies Inc., NexGen Veterinary, Soxa Formulations & Research Pvt. Ltd.

North America was the largest region in the veterinary intravenous (IV) solutions market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary intravenous (IV) solutions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary intravenous (IV) solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Veterinary intravenous (IV) solutions are sterile fluids administered directly into an animal’s bloodstream through a vein, usually via an IV catheter. These solutions are used in veterinary care to treat dehydration and electrolyte imbalances, deliver medications, or provide essential nutrients. They are crucial for maintaining or restoring fluid and electrolyte balance in animals, particularly during illness, surgery, or trauma.

The main types of veterinary intravenous (IV) solutions include isotonic crystalloids, dextrose solutions, synthetic colloids, natural colloids, and parenteral nutrition. Isotonic crystalloids are IV fluids with a solute concentration equal to that of the blood, helping to maintain fluid balance. These solutions are applicable to various animal types, including companion animals and production animals. They are used by different end-users such as veterinary hospitals and clinics, research institutes, and other related entities.

The veterinary intravenous solutions market research report is one of a series of new reports that provides veterinary intravenous solutions market statistics, including veterinary intravenous solutions industry global market size, regional shares, competitors with a veterinary intravenous solutions market share, detailed veterinary intravenous solutions market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary intravenous solutions industry. This veterinary intravenous solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The veterinary intravenous (IV) solutions market consists of sales of hypertonic solutions, isotonic solutions, and hypertonic solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.